Palivizumab

CAS No. 188039-54-5

Palivizumab( —— )

Catalog No. M36768 CAS No. 188039-54-5

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 347 Get Quote
5MG 549 Get Quote
10MG 785 Get Quote
25MG 1122 Get Quote
50MG 1518 Get Quote
100MG 2007 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Palivizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
  • Description
    Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    RSV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    188039-54-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998 Sep;102(3 Pt 1):531-7.?
molnova catalog
related products
  • Galiellalactone

    A small molecule, direct STAT3 inhibitor that inhibits the IL-6-induced SEAP expression with IC50 of 200-500 nM.

  • Corosolic acid

    Corosolic acid contains anti-angiogenic activity that can suppress FAK signaling induced by angiopoietin-1.

  • SD-1029

    SD-1029 (NSC 371488) is a potent inhibitor of Stat3 activation.